RESET-DMG Decoding the transcriptional and evolutionary maps of diffuse midline glioma to overcome treatment resistance
- Coordinator
- Uppsala Universitet, Sweden
- Runs
- 1 December 2026 to 30 November 2031
- Status
- Running
- EU funding
- €1.4m
- Total cost
- €1.4m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101300870
What the project is doing
In the project's own words, from its summary on CORDIS.
In Europe, cancer is the leading cause of disease-related deaths in children. Among these, the pediatric brain tumor diffuse midline glioma (DMG) is the most lethal, with a median survival of only 9–11 months. Surgical resection is not possible due to its location, and radiation –the current standard of care– provides only temporary benefit before resistance develops. A hallmark of DMG is loss of the H3K27me3 epigenetic repressive mark, which stalls cancer cells into proliferative, stem-like states driven by transcription factor (TF) dysregulation.
My research indicates that these TF-mediated programs not only sustain tumor growth but also influence treatment response, suggesting they represent actionable targets to both impair tumor progression and enhance the efficacy of targeted therapies. RESET-DMG will investigate how TF-mediated transcriptional states cooperate with genetic alterations to drive treatment resistance in DMG. Aim 1 will establish proof-of-concept that disrupting these transcriptional states enhances the efficacy of TP53 reactivation– a therapeutic strategy with particular promise for the >40% of DMGs retaining wild-type TP53.
This will be evaluated in patient-derived neurospheres, brain organoids, and orthotopic mouse xenograft models. Aim 2 will expand this question to eight clinically-relevant targeted therapies in DMG, generating resistant cell line models and profiling emerging cell populations with single-cell barcoding and multiome technologies across treatment modalities. Aim 3 will use predictive modelling to identify the features that contribute the most to treatment resistance in our generated cell line models, validating them in vitro and in a cohort of >70 human DMG samples, with the goal of informing therapeutic strategies for primary and relapsed disease.
Upon completion, I envision this interdisciplinary project will establish a framework for rational therapeutic combinations designed to overcome treatment resistance in DMG.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Uppsala Universitet | Uppsala | Sweden | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI